Phase 2 Transverse Myelitis Trial, Recruiting (NCT06697535)

Phase 2 Transverse Myelitis Trial, Recruiting NCT06697535 Sponsor: Guangzhou JOYO Pharma Co., Ltd Condition: Transverse Myelitis

Printed from Voxsanity (voxsanity.com.au) — NCT06697535 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Transverse Myelitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) based on the 2015 international diagnostic guidelines
Your blood tests show a positive result for a specific protein called AQP4-IgG (a marker linked to this condition)
You are currently experiencing an active/acute episode of NMOSD
If you are female, your pregnancy test at screening was negative, you and your partner have no plans for children, you agree to use two forms of non-pill contraception from screening until 6 months after the last dose of the study drug, and you have no plans to donate eggs or sperm
You have fully understood the study, are willing to take part, and have signed a consent form

Who may not be able to join:

You are currently pregnant or breastfeeding
You have a known or suspected allergy to any ingredient in the study drug, or you have a history of multiple allergies (confirm with trial site)
Your symptoms from the active episode started to improve before you could begin receiving the study drug
You are unable to have an MRI scan or a contrast-enhanced MRI scan (which uses a special dye injected to improve image clarity)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 731-84327919

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06697535

Sponsor: Guangzhou JOYO Pharma Co., Ltd

Phase: Phase 2

Status: Recruiting

Condition: Transverse Myelitis

Trial contact: +86 731-84327919

More information: https://clinicaltrials.gov/study/NCT06697535

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) based on the 2015 international diagnostic guidelines
Your blood tests show a positive result for a specific protein called AQP4-IgG (a marker linked to this condition)
You are currently experiencing an active/acute episode of NMOSD
If you are female, your pregnancy test at screening was negative, you and your partner have no plans for children, you agree to use two forms of non-pill contraception from screening until 6 months after the last dose of the study drug, and you have no plans to donate eggs or sperm
You have fully understood the study, are willing to take part, and have signed a consent form

Who may not be able to join:

You are currently pregnant or breastfeeding
You have a known or suspected allergy to any ingredient in the study drug, or you have a history of multiple allergies (confirm with trial site)
Your symptoms from the active episode started to improve before you could begin receiving the study drug
You are unable to have an MRI scan or a contrast-enhanced MRI scan (which uses a special dye injected to improve image clarity)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Guangzhou JOYO Pharma Co., Ltd

Registry

ClinicalTrials.gov

Start date

24 May 2023

Est. completion

28 February 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Proportion of participants achieving clinical recovery based on EDSS after 6 weeks of treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov